

Update on HCP POG drafting groups


HCPWP Plenary





Prioritising areas of work

- Survey to all eligible HCP organisations in 2021
- HCP POG meetings were not enough to collect input from organisations
- Establishment of 4 HCP POG `drafting groups'
 - Deliver concrete outputs on selected topic
 - For some topics, work required clinical experts
 in addition to policy officers



Drafting groups – progress update

- Frailty and older people considerations in medicine development and evaluation
 - Inclusion of functional measures and frailty in the development and evaluation of medicine for older adults: published in Lancet Health and Aging in November 2023
- Use of surrogate endpoints for regulatory approval
 - A comprehensive document addressing classification of surrogate endpoints and ethical considerations has been prepared; work is ongoing to split the document into different topics which can then lead to separate publications.

Drafting groups – progress update

- Pharmacovigilance with focus on medication errors
 - A comprehensive draft has been prepared:
 - Explores the EU pharmacovigilance system, from the perspective of healthcare professionals
 - Looks at the legislative framework, identifying areas where more support for HCPs could be envisaged, with specific attention to the identification and prevention of medication errors
 - Analysis from EMA perspective is ongoing

Drafting groups – progress update

Shortages of medicines

- Aim: bridging a gap in terms of having a comprehensive overview of HCP organisations' views on policy developments and practice implications regarding medicines shortages, clarifying aspects pertaining to current policy and instruments stemming from EMA extended mandate.
 - Part A addressing EMA extended mandate; mechanisms differing at times of crisis; recent developments.
 - Part B addressing guidance for HCPs in terms of proposed preventive and reactive shortage mitigation measures, common themes and relevance thereof; examples from different specialities as mini case studies.
 - Part C Discussion and proposal for next steps, incl. input from patient and consumer groups.
- Indicative timeline: draft for HCPWP consultation in Aug/Sep

Conclusion

- Valued group to strengthen engagement of eligible HCPOs in EMA activities
 - Supporting the link between EMA and HCPWP strategic priorities/workplan and the policy work developed by HCPOs.
- HCP POG to be maintained with following scope:
 - Tool for 'stakeholder listening' and enhanced early engagement with all eligible HCP organisations through policy officers;
 - A forum for EMA to provide updates on ongoing work and strategic priorities;
 - · A forum for all eligible organisations to provide input and raise issues or concerns with EMA at an earlier stage;
 - Ad-hoc drafting groups may be established on a temporary basis to deliver specific outputs, upon agreement of the HCPWP. Membership of drafting groups may include non-HCP POG members.



Any questions?

Further information

ivana.silva@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Telephone +31 (0)88 781 6000Send us a question Go to www.ema.europa.eu/contact

